pharmaceutical investing Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304
pharmaceutical investing Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
gold investing Roxgold Announces Interim Results of Bagassi South Infill and Extensional Drilling Program for the QV Prime Structure
Bahia Metals Files NI 43-101 Technical Report for Initial 313 Million Tonne Mangueiros Main Inferred Mineral Resource Estimate
GoldInxs Advances Fishpot Toward Maiden Drill Program with New 3D IP Survey, Magnetic and Virtual DRILL Results
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA
